Economic evaluation of sunitinib vs. interferon-alfa (IFN-alfa) in first-line treatment of Metastatic Renal Cell Carcinoma (MRCC) in Colombia

被引：0
|
作者：
Godoy, J., I [1 ]
Cardona, A. F. [2 ]
Alvis, N. [3 ]
Arango, C. H. [4 ]
Romero, M. [4 ]
Spath, A. [5 ]
Ramirez, P. [5 ]
Caceres, H. A. [5 ]
Quijano, M. F. [6 ]
机构：
[1] Cent Mil Hosp, Bogota DC, Colombia
[2] Hosp Univ San Ignacio, Bogota DC, Colombia
[3] Univ Cartagena, Cartagena, Colombia
[4] Synergia Consultoria & Gest SA, Bogota DC, Colombia
[5] Pfizer SA, Bogota DC, Colombia
[6] Univ Sabana, Bogota DC, Colombia
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70324-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A100 / A100
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO
    Salinas-Escudero, G.
    Contreras-Hernandez, I
    Mould-Quevedo, J.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
  • [22] COST-EFFECTIVENESS OF SUNITINIB (SU) VS SORAFENIB (SFN), TEMSIROLIMUS (TMS) AND BEVACIZUMAB plus INTERFERON-ALFA (BEV/IFN) AS FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) - ADAPTATION FOR THE SWEDISH HEALTH SERVICE
    Munir, U.
    Benedict, A.
    Borgman, B.
    Sandin, R.
    Harmenberg, U.
    Ullen, A.
    Sandstrom, P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 228 - 228
  • [23] Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma
    Rixe, O.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Oudard, S.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [24] COST-EFFECTIVENESS ANALYSIS OF SUNITINIB VERSUS INTERFERON ALFA FOR THE FIRST-LINE TREATMENT OF ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA IN SINGAPORE
    Pruis, S.
    Pearce, F.
    Aziz, Abdul M., I
    Wu, D. B.
    Ng, K. H.
    [J]. VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [25] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [26] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [27] COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VERSUS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN ECUADOR
    Torres Toala, F. G.
    Albuja Riofrio, M. F.
    Mould, J. F.
    Estevez, C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A139 - A139
  • [28] Sunitinib versus interferon - alfa in metastatic renal-cell carcinoma
    Irani, Jacques
    [J]. PROGRES EN UROLOGIE, 2007, 17 (05): : 996 - 996
  • [29] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Rixe, Olivier
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Kim, Sindy T.
    Chen, Isan
    Bycott, Paul W.
    Baum, Charles M.
    Figlin, Robert A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 115 - 124
  • [30] ECONOMIC EVALUATION OF SUNITINIB FOR THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Novikov, I
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A222 - A222
12345